What happened
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biotechnology company developing an experimental new lupus therapy, rose 16.8% in September, according to data from S&P Global Market Intelligence. Analyst attention following an important step forward for the company’s lead candidate pushed the stock higher.
Continue Reading Below
So what
Aurinia’s lead candidate, voclosporin, is in a pivotal study that could make it the first therapy specifically approved for the treatment of lupus nephritis. Late in September, the company finished enrolling patients into the Aurora study — which means 52-week kidney response data should be ready in 2019.
Estimates vary, but perhaps a million Americans have systemic lupus erythematosus, and around two-fifths eventually progress to kidney-threatening lupus nephritis. With this in mind, a Cantor Fitzgerald analyst recently issued a price target that suggested Aurinia stock has more than 200% upside.
Now what
Voclosporin’s chance for success in its ongoing pivotal study looks better than average, considering its performance in midstage testing. Last year, Aurinia showed us that adding its candidate to standard care led to significantly greater remission rates at 48 weeks. Providing a significant benefit in the larger setting could make voclosporin a blockbuster drug.
Advertisement
Aurinia also initiated a dry eye trial with voclosporin earlier this year that will put it up against Allergan’s former blockbuster Restasis. If successful, there could be further gains before the end of the year.
10 stocks we like better than Aurinia PharmaceuticalsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Aurinia Pharmaceuticals wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
